CMPX•benzinga•
Compass Therapeutics Reports Interim Phase 2 Data Of CTX-009 In Combination With Paclitaxel In Biliary Tract Cancers; Co. Reports 'CTX-009 Demonstrated a 42% Overall Response Rate Based on 10 Partial Responses in 24 Enrolled Patients'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga